Lucid Diagnostics (LUCD) EBIAT (2022 - 2025)
Historic EBIAT for Lucid Diagnostics (LUCD) over the last 4 years, with Q3 2025 value amounting to -$10.4 million.
- Lucid Diagnostics' EBIAT rose 1595.67% to -$10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.3 million, marking a year-over-year decrease of 1889.2%. This contributed to the annual value of -$45.5 million for FY2024, which is 1355.14% up from last year.
- Latest data reveals that Lucid Diagnostics reported EBIAT of -$10.4 million as of Q3 2025, which was up 1595.67% from -$4.4 million recorded in Q2 2025.
- In the past 5 years, Lucid Diagnostics' EBIAT ranged from a high of -$4.4 million in Q2 2025 and a low of -$26.9 million during Q1 2025
- Its 4-year average for EBIAT is -$13.1 million, with a median of -$12.3 million in 2022.
- Within the past 5 years, the most significant YoY rise in Lucid Diagnostics' EBIAT was 5966.38% (2025), while the steepest drop was 15356.2% (2025).
- Quarter analysis of 4 years shows Lucid Diagnostics' EBIAT stood at -$14.9 million in 2022, then grew by 27.45% to -$10.8 million in 2023, then dropped by 6.57% to -$11.5 million in 2024, then increased by 9.91% to -$10.4 million in 2025.
- Its EBIAT stands at -$10.4 million for Q3 2025, versus -$4.4 million for Q2 2025 and -$26.9 million for Q1 2025.